These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

By Robin Respaut and Maggie Fick SAN FRANCISCO (Reuters) -In what she calls the "wild west" of obesity medicines, ...

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

A new bill could make the price of prescription drugs known for weight loss cheaper for the state of Ohio to buy for its ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

If you’ve been waiting for the chance for weight loss injections to drop in price, there are more options turning up to ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

A bill would allow Ohio state employees to purchase GLP-1s from manufacturers, then would require the Department of ...